Mirum Pharmaceuticals, Inc. filings document operating results, product-sales disclosures, clinical program updates and governance matters for a rare disease biopharmaceutical company. Its 8-K reports furnish earnings releases, preliminary sales information, Regulation FD investor materials and other event disclosures tied to LIVMARLI, CHOLBAM, CTEXLI and investigational programs such as volixibat and brelovitug.
The company’s SEC record also covers capital-structure and transaction disclosures, including the completed Bluejay Therapeutics acquisition, related pro forma financial information and a PIPE financing. Proxy filings describe annual meeting matters, board elections, executive compensation and equity-plan governance, while registration details identify Mirum common stock as listed on the Nasdaq Global Market under MIRM.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 disclosing a proposed resale of 2,721 performance shares dated 03/15/2026. The filing also shows a sale by Jolanda Marie Howe of 2,594 common shares on 06/17/2026 for $264,458.30.
Mirum Pharmaceuticals SVP Jolanda Howe reported an open-market sale of 2,594 shares of Common Stock at $101.95 per share. After this transaction, she directly holds 5,835 shares. The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026, indicating the timing was scheduled in advance.
Mirum Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. As of the April 20, 2026 record date, 60,977,841 shares of common stock were outstanding and entitled to vote.
Stockholders elected three Class I directors—Lon Cardon, William Fairey, and Timothy Walbert—to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Mirum’s stockholders also ratified the selection of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
Mirum Pharmaceuticals, Inc. director Timothy P. Walbert reported equity awards consisting of restricted stock units and stock options. He received 1,980 restricted stock units, each representing a right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, but will in any case be fully vested on the date of Mirum’s 2027 annual stockholder meeting. After these awards, Walbert holds 1,980 RSUs and 3,772 options directly, reflecting compensation-related grants rather than open‑market trades.
Mirum Pharmaceuticals director Lon Cardon received new equity awards as part of his compensation. He was granted 1,980 restricted stock units, each representing the right to receive one share of common stock, and 3,772 stock options with an exercise price of $101.00 per share.
Both the RSUs and options vest on the first anniversary of the June 15, 2026 grant date, and in any event will be fully vested by the company’s 2027 annual stockholder meeting. After these awards, Cardon directly holds 1,980 RSUs and 3,772 options, with no shares bought or sold in this filing.
Mirum Pharmaceuticals director Saira Ramasastry reported new equity awards. She received 1,980 restricted stock units and stock options for 3,772 shares of common stock with an exercise price of 101 per share. Both awards vest on the first anniversary of the grant date, or earlier if fully vested by Mirum’s 2027 annual stockholder meeting. The options expire on June 14, 2036. These are compensation-related grants rather than open-market purchases or sales.
Mirum Pharmaceuticals director William Fairey reported new equity awards consisting of deferred stock units and stock options. He received 1,980 deferred stock units and options for 3,772 shares of common stock at an exercise price of $101.00 per share, all as compensation awards.
The options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service.
Mirum Pharmaceuticals director Laura Brege reported equity awards consisting of deferred stock units and stock options. She received 1,980 deferred stock units, each representing a contingent right to one share of common stock, and 3,772 stock options to buy common stock at an exercise price of $101.00 per share.
Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case will be fully vested by the company’s 2027 annual stockholder meeting. The options expire on June 14, 2036. Vested deferred stock units will be settled in common stock upon a change in control of Mirum or within 60 days after Brege’s separation from service.
Mirum Pharmaceuticals director Patrick J. Heron received new equity awards as part of his compensation. He was granted 1,980 deferred stock units and 3,772 stock options, each option giving the right to buy one share of common stock at an exercise price of $101.00 per share.
The stock options and deferred stock units vest on the first anniversary of the grant date, and in any case will be fully vested by the date of Mirum’s 2027 annual stockholder meeting. Each vested deferred stock unit will be settled in common stock upon a change in control of Mirum or within 60 days after his separation from service. These are grants and not open‑market purchases or sales.
Mirum Pharmaceuticals director Laurent Fischer received new equity awards in the form of deferred stock units and stock options. The filing shows a grant of 1,980 deferred stock units and 3,772 stock options, each tied to Mirum common stock.
The stock options carry an exercise price of $101.00 per share and expire on June 14, 2036. Both the options and deferred stock units vest on the first anniversary of the June 15, 2026 grant date, and in any case are fully vested by the date of Mirum’s 2027 annual stockholder meeting.
Each deferred stock unit represents a right to receive one share of common stock. Vested deferred stock units will be settled in stock upon the earlier of a change in control of Mirum or within 60 days after Fischer’s separation from service with the company.